Marino Garcia sold $18M of DNTH
CEO AND PRESIDENT at Dianthus Therapeutics, Inc. /DE/. 166,000 shares at an average of $108.11, traded Aug 7, 2026, filed Aug 7, 2026.
Score components
- +25RoleCEO
- +25Trade size$17.9M at market
- +20Share of holdings soldSold 72% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001669866-26-000010, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | MOption exercise Common Stock10b5-1 | +40,000 | $8.44 | $338k | 105,292 | Aug 7, 2026 |
| Aug 7, 2026 | MOption exercise Common Stock10b5-1 | +126,000 | $8.44 | $1.1M | 231,292 | Aug 7, 2026 |
| Aug 7, 2026 | SOpen-market sale Common Stock10b5-1 | -10,384 | $107.49 | $1.1M | 220,908 | Aug 7, 2026 |
| Aug 7, 2026 | SOpen-market sale Common Stock10b5-1 | -23,907 | $108.05 | $2.6M | 197,001 | Aug 7, 2026 |
| Aug 7, 2026 | SOpen-market sale Common Stock10b5-1 | -2,373 | $109.10 | $259k | 194,628 | Aug 7, 2026 |
| Aug 7, 2026 | SOpen-market sale Common Stock10b5-1 | -2,536 | $110.02 | $279k | 192,092 | Aug 7, 2026 |
| Aug 7, 2026 | SOpen-market sale Common Stock10b5-1 | -800 | $110.76 | $89k | 191,292 | Aug 7, 2026 |
| Aug 7, 2026 | SOpen-market sale Common Stock10b5-1 | -104,091 | $107.96 | $11M | 87,102 | Aug 7, 2026 |
| Aug 7, 2026 | SOpen-market sale Common Stock10b5-1 | -21,909 | $108.72 | $2.4M | 65,292 | Aug 7, 2026 |
| Aug 7, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -40,000 | $0.00 | $0 | 286,004 | Aug 7, 2026 |
| Aug 7, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -126,000 | $0.00 | $0 | 160,004 | Aug 7, 2026 |
Related signals
Other insiders at Dianthus Therapeutics, Inc. /DE/ and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Dianthus Therapeutics, Inc. /DE/ | Edward Carr CHIEF ACCOUNTING OFFICER | $2.0M 20,000 shares | -100% | |
| 33Weak | Dianthus Therapeutics, Inc. /DE/ | Simrat Randhawa EVP, Head of R&D | $2.5M 23,124 shares | -85% | |
| 30Weak | Dianthus Therapeutics, Inc. /DE/ | Simon Read director | $327k 2,778 shares | -100% | |
| 29Weak | Dianthus Therapeutics, Inc. /DE/ | Simon Read director | $304k 2,777 shares | -100% | |
| 40Moderate | Dianthus Therapeutics, Inc. /DE/ | Adam M Veness SVP, General Counsel and Sec. | $2.2M 20,000 shares | -522% | |
| 38Weak | Dianthus Therapeutics, Inc. /DE/ | Anne McGeorge director | $845k 7,750 shares | -100% | |
| 32Weak | Dianthus Therapeutics, Inc. /DE/ | Ryan Savitz EVP, CFO & CBO | $3.2M 31,249 shares | -100% | |
| 25Weak | Dianthus Therapeutics, Inc. /DE/ | Adam M Veness SVP, General Counsel and Sec. | $2.4M 30,000 shares | -100% | |
| 25Weak | Dianthus Therapeutics, Inc. /DE/ | Simrat Randhawa EVP, Head of R&D | $2.4M 26,530 shares | -87% | |
| 7Weak | Dianthus Therapeutics, Inc. /DE/ | Paula Soteropoulos director | $51k 599 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.